A 2-es típusú diabetes orális kezelése

Translated title of the contribution: Oral antidiabetic treatment of type 2 diabetes mellitus

A. Somogyi, Nagy Géza, Varga Tímea, Rosta Klára

Research output: Contribution to journalArticle

Abstract

Evidence based medical guidelines for the treatment of type 2 diabetes mellitus focus on three areas: lifestyle changes, radical treatment of cardiovascular risk factors and normalization of blood glucose levels. Type 2 diabetes mellitus can be characterized by peripheral insulin resistance, diminished secretion of insulin of the pancreas, and increased glucose production of the liver. The therapeutic agents used to treat T2DM beneficially influence one or more of these abnormalities. Metformin belongs to the first-line treatment of T2DM, which ameliorates peripheral insulin resistance and diminishes glucose production of the liver. Further therapeutic choices are sulfonylureas, which enhance insulin secretion, alpha-glycosidase inhibitors, and thiazolidinediones. In the clinical practice of the last few years incretin mimetic compounds and DPP4 inhibitors, which enhance incretin effect, have also been administered. In order to normalize blood glucose level, drugs with different mechanism of action can be coadministered and most of them can be supplemented with insulin treatment.

Original languageHungarian
Pages (from-to)145-154
Number of pages10
JournalOrvoskepzes
Volume85
Issue number2
Publication statusPublished - 2010

Fingerprint

Hypoglycemic Agents
Type 2 Diabetes Mellitus
Incretins
Insulin
Vascular Resistance
Insulin Resistance
Blood Glucose
Glucose
Thiazolidinediones
Glycoside Hydrolases
Metformin
Liver
Life Style
Pancreas
Guidelines
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Somogyi, A., Géza, N., Tímea, V., & Klára, R. (2010). A 2-es típusú diabetes orális kezelése. Orvoskepzes, 85(2), 145-154.

A 2-es típusú diabetes orális kezelése. / Somogyi, A.; Géza, Nagy; Tímea, Varga; Klára, Rosta.

In: Orvoskepzes, Vol. 85, No. 2, 2010, p. 145-154.

Research output: Contribution to journalArticle

Somogyi, A, Géza, N, Tímea, V & Klára, R 2010, 'A 2-es típusú diabetes orális kezelése', Orvoskepzes, vol. 85, no. 2, pp. 145-154.
Somogyi A, Géza N, Tímea V, Klára R. A 2-es típusú diabetes orális kezelése. Orvoskepzes. 2010;85(2):145-154.
Somogyi, A. ; Géza, Nagy ; Tímea, Varga ; Klára, Rosta. / A 2-es típusú diabetes orális kezelése. In: Orvoskepzes. 2010 ; Vol. 85, No. 2. pp. 145-154.
@article{08e9cc9286d642c49aa4cddab629dba4,
title = "A 2-es t{\'i}pus{\'u} diabetes or{\'a}lis kezel{\'e}se",
abstract = "Evidence based medical guidelines for the treatment of type 2 diabetes mellitus focus on three areas: lifestyle changes, radical treatment of cardiovascular risk factors and normalization of blood glucose levels. Type 2 diabetes mellitus can be characterized by peripheral insulin resistance, diminished secretion of insulin of the pancreas, and increased glucose production of the liver. The therapeutic agents used to treat T2DM beneficially influence one or more of these abnormalities. Metformin belongs to the first-line treatment of T2DM, which ameliorates peripheral insulin resistance and diminishes glucose production of the liver. Further therapeutic choices are sulfonylureas, which enhance insulin secretion, alpha-glycosidase inhibitors, and thiazolidinediones. In the clinical practice of the last few years incretin mimetic compounds and DPP4 inhibitors, which enhance incretin effect, have also been administered. In order to normalize blood glucose level, drugs with different mechanism of action can be coadministered and most of them can be supplemented with insulin treatment.",
keywords = "Guidelines, Oral antidiabetics, Recommendations, Type 2 diabetes mellitus",
author = "A. Somogyi and Nagy G{\'e}za and Varga T{\'i}mea and Rosta Kl{\'a}ra",
year = "2010",
language = "Hungarian",
volume = "85",
pages = "145--154",
journal = "Orvoskepzes",
issn = "0030-6037",
publisher = "Semmelweis Kiado",
number = "2",

}

TY - JOUR

T1 - A 2-es típusú diabetes orális kezelése

AU - Somogyi, A.

AU - Géza, Nagy

AU - Tímea, Varga

AU - Klára, Rosta

PY - 2010

Y1 - 2010

N2 - Evidence based medical guidelines for the treatment of type 2 diabetes mellitus focus on three areas: lifestyle changes, radical treatment of cardiovascular risk factors and normalization of blood glucose levels. Type 2 diabetes mellitus can be characterized by peripheral insulin resistance, diminished secretion of insulin of the pancreas, and increased glucose production of the liver. The therapeutic agents used to treat T2DM beneficially influence one or more of these abnormalities. Metformin belongs to the first-line treatment of T2DM, which ameliorates peripheral insulin resistance and diminishes glucose production of the liver. Further therapeutic choices are sulfonylureas, which enhance insulin secretion, alpha-glycosidase inhibitors, and thiazolidinediones. In the clinical practice of the last few years incretin mimetic compounds and DPP4 inhibitors, which enhance incretin effect, have also been administered. In order to normalize blood glucose level, drugs with different mechanism of action can be coadministered and most of them can be supplemented with insulin treatment.

AB - Evidence based medical guidelines for the treatment of type 2 diabetes mellitus focus on three areas: lifestyle changes, radical treatment of cardiovascular risk factors and normalization of blood glucose levels. Type 2 diabetes mellitus can be characterized by peripheral insulin resistance, diminished secretion of insulin of the pancreas, and increased glucose production of the liver. The therapeutic agents used to treat T2DM beneficially influence one or more of these abnormalities. Metformin belongs to the first-line treatment of T2DM, which ameliorates peripheral insulin resistance and diminishes glucose production of the liver. Further therapeutic choices are sulfonylureas, which enhance insulin secretion, alpha-glycosidase inhibitors, and thiazolidinediones. In the clinical practice of the last few years incretin mimetic compounds and DPP4 inhibitors, which enhance incretin effect, have also been administered. In order to normalize blood glucose level, drugs with different mechanism of action can be coadministered and most of them can be supplemented with insulin treatment.

KW - Guidelines

KW - Oral antidiabetics

KW - Recommendations

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=82555201023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82555201023&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:82555201023

VL - 85

SP - 145

EP - 154

JO - Orvoskepzes

JF - Orvoskepzes

SN - 0030-6037

IS - 2

ER -